A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy and 30 Gray Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Inclusion Criteria:

- Histologic diagnosis of classical, CD30 positive Hodgkin lymphoma

- FDG-avid disease by FDG-PET/CT and measurable disease of at least 1.5 cm by CT

- Ann Arbor Stage I or II disease

- At least one of the following unfavorable risk factors as defined by GHSG: bulky
mediastinal mass (≥one-third maximum transverse thoracic diameter on
Posterior-Anterior/Lateral Chest X-ray or ≥10cm by CT imaging in axial plane), ESR ≥
50mm/h or ESR ≥30 mm/h in patients with "B" symptoms, extranodal involvement, or 3 or
more involved lymph node sites.

- Females of childbearing age must be on an acceptable form of birth control

- Age between 18 and 60

Exclusion Criteria:

- Cardiac ejection fraction ≤ 50%

- Hemoglobin-adjusted diffusing capacity for carbon monoxide < 60%

- ANC≤1000/μl and Platelets≤75,000/μl

- Total bilirubin ≥ 2.0 mg/dl in the absence of a history of Gilbert's disease

- Known pregnancy or breast-feeding

- Medical illness unrelated to Hodgkin Lymphoma, which, in the opinion of the attending
physician and/or principal investigator, makes participation in this study
inappropriate.

- Peripheral neuropathy > grade 1

- Patients receiving treatment with systemic steroids